Patrick Aebischer was trained as an MD (1980) and a Neuroscientist (1983) at the University of Geneva and Fribourg in Switzerland.
From 1984 to 1992, he worked at Brown University in Providence (Rhode Island, USA), as an Assistant and then Associate Professor of Medical Sciences. In 1991, he became the chairman of the Section of Artificial Organs, Biomaterials and Cellular Technology of the Division of Biology and Medicine of Brown University. In the fall of 1992, he returned to Switzerland as a Professor and Director of the Surgical Research Division and Gene Therapy Center at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne.
In 1999, Patrick Aebischer was nominated President of the Swiss Federal Institute of Technology in Lausanne (EPFL) by the Swiss Federal Council. He took office as President on March, 2000 and since January 2004, he is a member of the ETH-Board.
His current research focuses on the development of cell and gene transfer approaches for the treatment of neurodegenerative diseases. Patrick Aebischer is a member of numerous professional societies, both in Europe and America. He is a fellow of the American Institute for Medical and Biological Engineering and a fellow of the Swiss Academy of Medicine. Patrick Aebischer is also a founder of two biotechnology companies: CytoTherapeutics (today Stem Cell Inc) and Modex Therapeutics (today IsoTis).